Answers are grounded in this paper and cite their sources.
Disease-modifying treatments have transformed the management and prognosis of spinal muscular atrophy (SMA) over the last eight years. Since the very fi rst phase III trial conducted in SMA type 1, 1 it became clear that the timing of treatment is key to ensuring the best ef-fi cacy. This is not surprising, as SMA is caused by the death of alpha motoneurons that do not replicate. The goal of treatments is to halt the irreversible mechanism of degeneration in motoneurons that are still alive.
No takes yet. Share an insight, caveat, or question.
Laurent Servais (2024) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: